The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer
© Hu et al.; licensee BioMed Central Ltd. 2010
Received: 2 September 2009
Accepted: 8 March 2010
Published: 8 March 2010
HJURP (Holliday Junction Recognition Protein) is a newly discovered gene reported to function at centromeres and to interact with CENPA. However its role in tumor development remains largely unknown. The goal of this study was to investigate the clinical significance of HJURP in breast cancer and its correlation with radiotherapeutic outcome.
We measured HJURP expression level in human breast cancer cell lines and primary breast cancers by Western blot and/or by Affymetrix Microarray; and determined its associations with clinical variables using standard statistical methods. Validation was performed with the use of published microarray data. We assessed cell growth and apoptosis of breast cancer cells after radiation using high-content image analysis.
HJURP was expressed at higher level in breast cancer than in normal breast tissue. HJURP mRNA levels were significantly associated with estrogen receptor (ER), progesterone receptor (PR), Scarff-Bloom-Richardson (SBR) grade, age and Ki67 proliferation indices, but not with pathologic stage, ERBB2, tumor size, or lymph node status. Higher HJURP mRNA levels significantly decreased disease-free and overall survival. HJURP mRNA levels predicted the prognosis better than Ki67 proliferation indices. In a multivariate Cox proportional-hazard regression, including clinical variables as covariates, HJURP mRNA levels remained an independent prognostic factor for disease-free and overall survival. In addition HJURP mRNA levels were an independent prognostic factor over molecular subtypes (normal like, luminal, Erbb2 and basal). Poor clinical outcomes among patients with high HJURP expression were validated in five additional breast cancer cohorts. Furthermore, the patients with high HJURP levels were much more sensitive to radiotherapy. In vitro studies in breast cancer cell lines showed that cells with high HJURP levels were more sensitive to radiation treatment and had a higher rate of apoptosis than those with low levels. Knock down of HJURP in human breast cancer cells using shRNA reduced the sensitivity to radiation treatment. HJURP mRNA levels were significantly correlated with CENPA mRNA levels.
HJURP mRNA level is a prognostic factor for disease-free and overall survival in patients with breast cancer and is a predictive biomarker for sensitivity to radiotherapy.
The centromere has long been recognized as a locus important for proper cell division and accurate partitioning of chromosomes into daughter cells [1–3]. Centromeres are the chromatin regions associated with kinetochores, which are massive multi-protein complexes that mediate chromosome segregation and the mitotic checkpoint . There is mounting evidence that kinetochores become functionally unstable during oncogenesis resulting in segregation defects, chromosome instability, and cancer development [4–6].
Holliday Junction Recognition Protein (HJURP, also known as hFLEG1), which is a newly discovered gene, was reported to be overexpressed in lung cancer cells through genome-wide expression profile analysis . By quantitative RT-PCR, Valente et al found that the HJURP expression levels significantly differ between glioblastoma resection tumor and non-neoplastic white matter . Additionally it was observed that the expression level of HJURP in glioblastoma was changed about nine fold compared to typically benign pilocytic astrocytomas by microarray profile analysis . It has also been reported that HJURP is involved in DNA double-strand break repair pathway through interaction with MSH5 and NBS1 . Recently two groups have shown that HJURP functions at the level of the centromere, and is required for centromere protein A (CENPA) centromeric localization, for loading of new CENPA nucleosomes, and for accurate chromosomal segregation [10–12]. A majority of cancer cells tend to gain and lose chromosomes at each mitotic division and are found to be aneuploid and chromosomally instable. Thus these findings support the hypothesis that alterations in HJURP might play an important role in cancer development. We investigated whether altered expression levels of HJURP are associated with adverse clinical outcomes using cohorts of patients with breast cancer.
Materials and methods
Cell lines and cell lysates
The list of breast cancer cell lines and immortalized non-malignant mammary epithelial cells used in these investigations.
Additional cell line growth conditions and subtypes
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
Ham's F12+5% FBS+IHc
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
H14 medium +10 ng/ml EGF
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
37°C, 5% CO2
For Western blots, 10 μg of protein extracts per lane were electrophoresed with denaturing sodium doedecyl sulfate (SDS)-polyacrylamide gels (4% to 12%), transferred to PVDF membranes (Millipore, Temecula, CA, USA), and incubated with HJURP antibody 1:500 (Rabbit, HPA008436, Sigma-Aldrich, St. Louis, MO, USA) and actin (goat, sc-1616, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted with blocking buffer (927-40000, LI-COR Biosciences, Lincoln, NE, USA) The membranes were washed four times with TBST and treated with 1:10,000 dilution of Alex Fluor 680 donkey anti-rabbit (A10043, Invitrogen, Carlsbad, CA, USA) and IRDye 800CW conjugated donkey anti-goat (611-731-127, Rockland, Gilbertsville, PA, USA) to detect HJURP and actin respectively. The signals were detected by infrared imaging (LI-COR Biosciences, Lincoln, NE, USA). Images were recorded as TIFF files for quantification.
Protein levels were measured by quantifying infrared imaging recorded from labeled antibodies using Scion Image . For each protein, the blots were made for 7 sets of 11 cell lines, each set including the same pair (SKBR3 and MCF12A) to permit intensity normalization across sets. A basic multiplicative normalization was carried out by fitting a linear mixed effects model to log intensity values, and adjusting within each set to equalize the log intensities of the pair of reference cell lines across the sets.
Detailed patient information has been described in our previous studies . This analysis is based on previously reported comparative genomic hybridization (CGH) and a gene expression profile of 130 tumors from UC San Francisco and the California Pacific Medical Center collected between 1989 and 1997.
The shRNA sequences were (forward) 5'-GATCCCC GAGCGATTCATCTTCATCA TTCAAGAGA TGATGAAGATGAATCGCTC TTTTTGGAAA-3' and (reverse) 5'-AGCT TTTCCAAAAA GAGCGATTCATCTTCATCA TCTCTTGAA TGATGAAGATGAATCGCTC GGG-3' synthesized from IDT (Integrated DNA Technologies, Inc., San Diego, CA, USA). HJURP shRNA was cloned into BglII and HindIII cleavage sites of pSUPER.retro.puro vector based on manufactory's instruction (OligoEngine, Seattle, WA, USA). HJURP shRNA expression vector were confirmed by direct DNA sequencing.
Retroviral packaging and infection
HJURP shRNA (or empty) retroviral vectors along with packaging system pHit60 and pVSVG vectors were then co-transfected into the HEK 293 Phoenix ampho packaging cells (ATCC, Manassas, VA, USA) by using FuGENE6 transfection reagent (Roche, Lewes, UK) according to the instruction to produce retroviral supernatants. Forty-eight hours after transfection, the virus-containing supernatant was filtered through a 0.45 μm syringe filter. Retroviral infection was performed by adding filtered supernatant to a MDAMB231 cell line cultured on 10 cm dishes with 50% confluent in the presence 4 ug/ml of polybrene (Sigma, St. Louis, MO, USA). Six hours after infection, the medium was changed with fresh medium. After 48 hours, infected cells were selected by adding 5 μg/ml puromycin (Sigma) to the culture medium for 72 hours and then maintained in complete medium with 2 μg/ml puromycin. Down-regulation of HJURP expression was confirmed by Western blot analysis.
High content imaging to assess cell number and apoptotic cells
The effects on cell growth and apoptosis were assessed by a Cellomics high-content image screening system (Cellomics, Thermo Fisher Scientfic Inc., Pittsburgh, PA, USA) after breast cancer cells exposed to a single dose of 0 (sham), 1, 2, 4, 6, 8 or 10 Gy X-ray radiation emitted from an irradiator (model 43855F, Faxitron X-ray Corporation, Lincolnshire, IL, USA). Live cells in 96 well plates with six replicates from each treatment were stained with 1 μmol/L YO-PRO-1 positive cells.
Spearman's correlation coefficient and test were used to examine the relationship between HJURP mRNA level and its protein level in the cell line studies, and the relationship with age, tumor size in the tumor studies, and CENPA mRNA level. The association between HJURP mRNA level and clinical factors, such as estrogen receptor (ER), progesterone receptor (PR), ERBB2 and lymph node status, pathological stage, Scarff-Bloom-Richardson (SBR) grade, was analyzed by Mann-Whitney U (for two groups) or Kruskal-Wallis H (for more than two groups) test. Kaplan-Meier plots were constructed and a long-rank test was used to determine differences among disease free and overall survival curves according to HJURP expression level or radiotherapy. Multivariate analyses were carried out to examine whether HJURP expression is an independent prognostic factor for survival when adjusting for other covariates (age, ER, PR, lymph node, pathologic stage, SBR grade, tumor size) or the molecular subtypes (normal like, luminal, Erbb2 and Basal) using Cox proportional-hazard regression. In addition, the relation between HJURP expression and survival was explored in microarray data sets by dividing the cases from each cohort into a group with high (top one-third), moderate (middle one-third), and low (bottom one-third) level of expression. All analyses were performed by SPSS 11.5.0 for Windows. A two-tailed P-value of less than 0.05 was considered to indicate statistical significance.
HJURPis overexpressed in breast cancer
HJURPmRNA level is an independent prognostic biomarker for poor clinical outcome
Results of multivariate analysis of independent prognostic factors in patients with breast cancer using Cox regression
Hazard ratio (95% CI)
Hazard ratio (95% CI)
2.05 (1.18 to 3.58)
1.83 (1.11 to 3.01)
Lymph node (positive)
3.76 (1.16 to 12.25)
2.72 (1.08 to 6.88)
2.23 (1.08 to 4.59)
1.85 (0.94 to 3.63)
1.32 (0.97 to 1.79)
1.34 (1.02 to 1.77)
1.01 (0.99 to 1.05)
1.03 (1.004 to 1.053)
High SBR Grade
0.76 (0.33 to 1.75)
1.00 (0.50 to 2.00)
0.63 (0.21 to 1.94)
0.86 (0.33 to 2.25)
0.90 (0.33 to 2.50)
0.95 (0.40 to 2.26)
Both HJURP mRNA levels and molecular subtypes are independent prognostic factors in patients with breast cancer using Cox regression#
Hazard ratio (95% CI)
Hazard ratio (95% CI)
High vs Low
3.26 (2.01 to 5.28)
3.23 (1.85 to 5.62)
Moderate vs Low
3.34 (2.11 to 5.27)
2.89 (1.68 to 4.95)
HJURPmRNA level predicts the sensitivity to radiation treatment in breast cancer patients and cell lines
Co-overexpression of HJURPand CENPA in breast cancer
The current study is the first to report that HJURP is overexpressed in breast cancer cell lines and primary human breast cancer compared to non-malignant human mammary epithelial cells and normal breast tissues. High HJURP mRNA expression is significantly associated with both shorter disease-free and overall survival which were validated in five independent clinical datasets for breast cancer. Furthermore, HJURP is a predictive marker for sensitivity of radiotherapy, indicating levels of HJURP mRNA and protein in breast cancer patients are clinically relevant.
Although we found HJURP mRNA levels were not associated with ERBB2 status, the mRNA levels of HJURP was still found significantly higher in triple-negative (ER negative, PR negative, ERBB2/HER2/neu not overexpressed) breast cancer, possibly due to the fact that a higher HJURP mRNA level is significantly associated with ER or PR negative status. Triple negative breast cancer has distinct clinical and pathological features, and also has relatively poor prognosis and aggressive behavior [18–20], consistent with our finding that high HJURP expression is associated with a bad prognosis. Furthermore, our studies showed that the prognostic effect of HJURP mRNA level on survival is independent of the clinical factors, such as age, lymph node, pathological stage, SBR grade, ER, PR, tumor size, and the molecular subtypes. In addition, we found there is a significant correlation between HJURP expression and Ki67 proliferation indices; however, HJURP expression is a better biomarker than Ki67 proliferation indices for the predication of prognosis.
It is very interesting to find that the HJURP mRNA level is a predictive marker for radiotherapy sensitivity. Our results showed that patients with low mRNA levels of HJURP already had a good prognosis and could not get further benefit from radiotherapy, suggesting these patients may not necessarily benefit from receiving radiotherapy. However, patients with high HJURP mRNA levels could increase their survival with radiotherapy, but they still had a worse prognosis than those with low levels as found in Dataset 3 (Figure 4c) and Dataset 4 (Figure 5a) where almost all patients received radiotherapy with or without additional benefit. Thus a high level of HJURP is overall associated with poor prognosis. Although we note our findings will require replication in additional independent and larger cohorts, our in vitro studies further confirmed that breast cancer cells with high levels of HJURP are more sensitive to radiation treatment, and even more convincingly, knock down of HJURP by shRNA reduces the sensitivity to radiation. The radiation induced more apoptosis in these cells, consistent with clinical findings. A previous report showed that HJURP interacts with proteins hMSH5 and NBS1, suggesting HJURP is involved in the DNA double-strand break repair process . The understanding of the roles that HJURP plays in DNA repair and cell death in response to DNA damage may provide new insights into the molecular mechanisms of breast tumor development and may help to improve breast cancer therapies. In addition, we found that cells with HJURP shRNA grew slowly (data not shown), which is consistent with the finding that the double time of cell lines was negatively correlated with HJURP protein level, indicating HJURP plays an important role in cell proliferation. Thus one of the reasons why the ability of HJURP to act as a marker for prognosis and response to radiotherapy may be linked to its control of cell proliferation.
HJURP has recently been reported to interact with CENP-A for the purpose of localizing CENP-A and loading new CENP-A nucleosomes on the centromere [11, 12]. CENP-A is the key determinant of centromere formation and kinetochore assembly, which regulate the complex job of attaching chromosomes to the mitotic spindle; ensuring that those attachments are correct; signalling a delay in mitotic progression if they are not, and regulating the movements of the chromosomes towards the spindle poles in anaphase. Thus overexpression of HJURP in human breast cancer may be similar to overexpression of mitotic kinases, such as Aurora kinases, which induce genomic instability that is one of the hallmarks for tumor development. In this study we showed that HJURP mRNA levels are highly significantly correlated with CENPA mRNA levels in human breast cancer cell lines and primary breast tumors. Such correlation is also found in other types of human cancer, such as cancers from lung, ovary, prostate (data not shown), suggesting that compatible mRNA levels of HJURP and CENPA might be required for tumor progression. Further investigation of the interaction between HJURP and CENPA for breast cancer development will be carried out in our future studies.
The expression level of HJURP has an independent prognostic impact for both disease-free and overall survival in breast cancer, and is a predictive biomarker for radiotherapy. Further investigations of the mechanisms of HJURP in tumor development and its association with sensitivity to radiotherapy are clearly warranted.
centromere protein A
Comparative Genomic Hybridization
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2: neuro/glioblastoma derived oncogene homolog
Gene Expression Omnibus
Holliday Junction Recognition Protein
- SBR grading:
The research was supported by the National Institutes of Health, National Cancer Institute grant R01 CA116481 (JHM); by the Director, Office of Science, Office of Biological & Environmental Research, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231, by the National Institutes of Health, National Cancer Institute grants P50 CA 5820, the P30 CA 82103, and the U54 CA 112970 (JWG).
- Morris CA, Moazed D: Centromere assembly and propagation. Cell. 2007, 128: 647-650. 10.1016/j.cell.2007.02.002.PubMedView ArticleGoogle Scholar
- Vagnarelli P, Ribeiro SA, Earnshaw WC: Centromeres: old tales and new tools. FEBS Lett. 2008, 582: 1950-1959. 10.1016/j.febslet.2008.04.014.PubMedView ArticleGoogle Scholar
- Brar GA, Amon A: Emerging roles for centromeres in meiosis I chromosome segregation. Nat Rev Genet. 2008, 9: 899-910. 10.1038/nrg2454.PubMedPubMed CentralView ArticleGoogle Scholar
- Cleveland DW, Mao Y, Sullivan KF: Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell. 2003, 112: 407-421. 10.1016/S0092-8674(03)00115-6.PubMedView ArticleGoogle Scholar
- Gonçalves Dos Santos, Silva A, Sarkar R, Harizanova J, Guffei A, Mowat M, Garini Y, Mai S: Centromeres in cell division, evolution, nuclear organization and disease. J Cell Biochem. 2008, 104: 2040-2058. 10.1002/jcb.21766.View ArticleGoogle Scholar
- Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005, 5: 773-785. 10.1038/nrc1714.PubMedView ArticleGoogle Scholar
- Kato T, Sato N, Hayama S, Yamabuki T, Ito T, Miyamoto M, Kondo S, Nakamura Y, Daigo Y: Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 2007, 67: 8544-8553. 10.1158/0008-5472.CAN-07-1307.PubMedView ArticleGoogle Scholar
- Valente V, Teixeira SA, Neder L, Okamoto OK, Oba-Shinjo SM, Marie SK, Scrideli CA, Paçó-Larson ML, Carlotti CG: Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol. 2009, 10: 17-10.1186/1471-2199-10-17.PubMedPubMed CentralView ArticleGoogle Scholar
- Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG, Toledo S, Moreira-Filho CA, Zago MA, Simpson AJ, Caballero OL: Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer. 2008, 122: 807-815. 10.1002/ijc.23189.PubMedView ArticleGoogle Scholar
- Sanchez-Pulido L, Pidoux AL, Ponting CP, Allshire RC: Common ancestry of the CENP-A chaperones Scm3 and HJURP. Cell. 2009, 137: 1173-1174. 10.1016/j.cell.2009.06.010.PubMedPubMed CentralView ArticleGoogle Scholar
- Dunleavy EM, Roche D, Tagami H, Lacoste N, Ray-Gallet D, Nakamura Y, Daigo Y, Nakatani Y, Almouzni-Pettinotti G: HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell. 2009, 137: 485-497. 10.1016/j.cell.2009.02.040.PubMedView ArticleGoogle Scholar
- Foltz DR, Jansen LE, Bailey AO, Yates JR, Bassett EA, Wood S, Black BE, Cleveland DW: Centromere-specific assembly of CENP-a nucleosomes is mediated by HJURP. Cell. 2009, 137: 472-484. 10.1016/j.cell.2009.02.039.PubMedPubMed CentralView ArticleGoogle Scholar
- Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10: 515-527. 10.1016/j.ccr.2006.10.008.PubMedPubMed CentralView ArticleGoogle Scholar
- Scion Corporation Home Page. Scion Corporation Home Page, [http://www.scioncorp.com]
- Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006, 10: 529-541. 10.1016/j.ccr.2006.10.009.PubMedView ArticleGoogle Scholar
- Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, Bloom G, Anderson T, White J, Quackenbush J, Yeatman T: Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat. 2010, 119: 335-46. 10.1007/s10549-009-0344-y.PubMedPubMed CentralView ArticleGoogle Scholar
- Gene Expression Omnibus (GEO) Main Page. Gene Expression Omnibus (GEO) Main page, [http://www.ncbi.nlm.nih.gov/geo]
- Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn van de M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.PubMedPubMed CentralView ArticleGoogle Scholar
- Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14: 1368-1376. 10.1158/1078-0432.CCR-07-1658.PubMedView ArticleGoogle Scholar
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin Cancer Res. 2007, 13: 4429-4434. 10.1158/1078-0432.CCR-06-3045.PubMedView ArticleGoogle Scholar
- Pawitan Y, Bjöhle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedrén S, Bergh J: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7: R953-964. 10.1186/bcr1325.PubMedPubMed CentralView ArticleGoogle Scholar
- Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C, TRANSBIG Consortium: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007, 13: 3207-3214. 10.1158/1078-0432.CCR-06-2765.PubMedView ArticleGoogle Scholar
- Vijver van de MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, Velde van der T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.PubMedView ArticleGoogle Scholar
- Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.PubMedView ArticleGoogle Scholar
- Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66: 10292-10301. 10.1158/0008-5472.CAN-05-4414.PubMedView ArticleGoogle Scholar
- Robustness, Scalability, and Integration of a Wound-Reponse Gene Expression Signature in Predicting Breast Cancer Survival. [http://microarray-pubs.stanford.edu/wound_NKI]
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.